22
2021.04
HyaMab NKG2A Monoclonal Antibody Clinical Trial Application Approved in the United States
On May 7, 2021, Shanghai Huaiyue Biotechnology Co., Ltd. announced that the company's research immune checkpoint project NKG2A monoclonal antibody new drug clinical trial application (IND) has been approved in the United States. The NKG2A monoclonal antibody is expected to start the enrollment of American patients in the second half of 2021. In the future, it will explore the combination of PD-L1 and other antibodies.